The world's most expensive drugs list

The US GoodRx website announced the list of the top 10 most expensive drugs in the worl.

The world's top 10 most expensive drugs list Novartis' SMA gene therapy Zolgensma $125 million orphan drugs

10 Soliris® (eculizumab)

Soliris® (eculizumab)

Sulevar (eculizumab) is a monoclonal antibody that inhibits terminal complement (C5a and C5b) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome in adults and children syndrome (aHUS) and adult neuromyelitis optica spectrum disorder (NMOS.

Suli Rui Adult and Pediatric Paroxysmal Nocturnal Hemoglobinuria Developed by Alexion Pharma, USA

Packaging of Soliris and its availability

09 Ravicti

Ravicti

Glyceryl phenylbutyrate is a small molecule of nitrogen binding agent developed by HorizonPharma for the long-term treatment of some patients with urea cycle disorder (UCD) aged 2 years or old.

Glycerides phenylbutyrate HorizonPharma developed the drug for long-term treatment of patients with an annual per capita expenditure of $ 695,000

Structure and listing of Ravicti

08 Blincyto (blinatumomab)

Blincyto (blinatumomab)

Binatumomab is a bispecific antibody (CD3 and CD19) developed by Amgen for the treatment of Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (rrAL.

blinatumomab is developed by Amgen for the treatment of Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia

Mechanism of action and dosing cycle of Blincyto

07 Brineura

Brineura

Brineura is an enzyme replacement therapy developed by BioMari.

Brineura BioMarin develops first therapy for late-onset infantile neuronal ceroid lipofuscinosis with annual cost of up to $730,000

Intracerebroventricular infusion system device diagram

06 Folotyn (Pralatrexate)

Folotyn (Pralatrexate)

Pralatrexate is a small molecule inhibitor of folic acid metabolism developed by Allos Therapeutic.

Pralatrexate Allos Therapeutics' first-in-class dihydrofolate reductase inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma

The structure and listing of Folotyn

05 Luxturna

Luxturna

Luxturna is the first approved gene therapy injection developed by Spark Therapeutics for the treatment of Leber congenital amaurosis (LCA) caused by RPE65 gene mutation (the first approved in the United States at the end of 2017.

Luxturna SparkTherapeutics Develops First Approved Gene Therapy Injection

Schematic diagram of the mechanism of action of Luxturna

04 Myalept

Myalept

Metriptine was developed by Amryt for the treatment of leptin deficiency complications in patients with congenital or acquired systemic lipodystrophy

Metriptine was developed by Amryt for the treatment of leptin deficiency complications in patients with congenital or acquired systemic lipodystrop.

Schematic diagram of the mechanism of action of Myalept

03 Danyelza

Danyelza

Nocetuzumab is a monoclonal antibody targeting the ganglioside GD2 developed by Y-mAbs for the treatment of bone or bone marrow neuroblastoma

A monoclonal antibody targeting the ganglioside GD2 for the treatment of neuroblastoma in the bone or bone marrow by Y-mAbs, the company 's annual treatment cost is about $970,000

Danyelza Mechanism of Action and Treatment Cycle

02 Zokinvy (Lonafarnib)

Zokinvy (Lonafarnib)

Lonafanib is a small molecule drug developed by EigerBioPharmaceuticals for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeria-like Laminopathy (PL) , which is an oral farnesyl transfer Enzyme inhibitor that reduces the accumulation of progerin in the nucleus by inhibiting the prenylation of progeri.

Lonafanib EigerBioPharmaceuticals developed a small molecule drug for the treatment of Hutchinson-Gilford Progeria Syndrome and Progeria-like Laminopathy Approved by the.

Zokinvy's structural formula

01 Zolgensma

Zolgensma

OAV101 injection is an AAV gene drug developed by NovartisPharma AG for the treatment of Spinal Muscular Atrophy (SMA.

OAV101 injection NovartisPharma AG developed an AAV gene drug for the treatment of spinal muscular atrophy and was first approved in the United States in 201 The annual treatment cost is about 12 million US dollars

references:

references:

https:// https://https:// https://https://luxturnah.

https://luxturnah.

https://myale.